SureTrader
Home > Boards > US Listed > Biotechs > Advaxis, Inc. (ADXS)

ADXS Board of Directors, please consider putting the

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (8) | Next 10 | Previous | Next
fbg0316 Member Profile
 
Followed By 7
Posts 3,499
Boards Moderated 0
Alias Born 12/14/09
160x600 placeholder
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 2/21/2018 4:20:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/21/2018 4:17:01 PM
Advaxis Announces Proposed Public Offering of Common Stock Business Wire - 2/21/2018 4:05:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/15/2018 5:29:09 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/13/2018 5:33:13 PM
Advaxis Submits Conditional Marketing Authorization Application for Axalimogene Filolisbac for the Second-Line Treatment of M... Business Wire - 2/13/2018 8:30:00 AM
Advaxis Announces Publication of Phase 2 Results Evaluating Axalimogene Filolisbac for the Treatment of Recurrent Metastatic ... Business Wire - 2/12/2018 9:15:00 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 2/6/2018 5:02:31 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/2/2018 4:37:57 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/2/2018 4:37:57 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/2/2018 4:37:57 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 1/29/2018 5:04:42 PM
Data Highlighting Advaxis’ Antigen Delivery Platform Accepted for Multiple Presentations at 2018 Keystone Symposia Conferen... Business Wire - 1/29/2018 8:00:00 AM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 1/25/2018 5:04:55 PM
Traders News Source Issues Stocks on Watch and a New Feature Report InvestorsHub NewsWire - 1/25/2018 8:05:00 AM
Advaxis’ Immunotherapy in Combination with Chemoradiation Highlighted as Potential Treatment for Anal Cancer in Internation... Business Wire - 1/25/2018 8:00:00 AM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 1/9/2018 5:18:37 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/3/2018 6:02:03 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/3/2018 6:01:39 PM
Annual Report (10-k) Edgar (US Regulatory) - 12/21/2017 6:05:52 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/20/2017 4:21:23 PM
Advaxis Reports Fiscal Year 2017 Financial Results and Provides a Business Update Business Wire - 12/20/2017 4:15:00 PM
Aratana Therapeutics Granted Conditional License for a Canine Osteosarcoma Therapeutic PR Newswire (US) - 12/20/2017 8:05:00 AM
Advaxis to Host Business Update and Fiscal Year End 2017 Financial Results Conference Call on December 21, 2017 Business Wire - 12/14/2017 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/4/2017 4:35:17 PM
fbg0316   Tuesday, 08/22/17 10:26:25 AM
Re: None
Post # of 55810 
ADXS Board of Directors, please consider putting the company on the auction block and selling for $20 to $25 ($800 million to $1 billion valuation). Arguably, this would be in the best interest of 1) patients (getting the constructs to market faster with trial execution done by the expertise of a larger pharma or biotech) and 2) ADXS investors (who are down 50% from the recapitalization price of $12 over the last four years). Why risk putting into place another CEO who turns out to fumble in advancing the platform (Moore) or one who turns out to be unethical and puts his personal financial interests above shareholder interests (O'Connor). In the latest corporate presentation, you cite around $1 billion of potential future deal value based on current collaborations - you should be able to sell the entire company for approximately this value ($20 to $25 share price). Do what's right for the company, its patients and investors.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (8) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist